State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, PR China; School of Bioscience and Technology, Chengdu Medical College, Chengdu 610500, PR China.
Department of Ultrasoundx, West China Hospital, Sichuan University, Chengdu 610041, PR China.
J Control Release. 2022 Dec;352:1116-1133. doi: 10.1016/j.jconrel.2022.11.026. Epub 2022 Nov 21.
As a novel non-apoptotic cell death pathway, ferroptosis can effectively enhance the antitumor effects of photodynamic therapy (PDT) by disrupting intracellular redox homeostasis. However, the reported nanocomposites that combined the PDT and ferroptosis are cumbersome to prepare, and the unfavorable tumor microenvironment also severely interferes with their tumor suppressive effects. To address this inherent barrier, this study attempted to explore photosensitizers that could activate ferroptosis pathway and found that the photosensitizer aloe-emodin (AE) could induce cellular ferroptosis based on its specific inhibiting activity to Glutathione S-transferase P1(GSTP1), a key protein for ferroptosis. Herein, we prepared AE@RBC/Fe nanocrystals (NCs) with synergistic PDT and ferroptosis therapeutic effects by one-step emulsification to obtain AE NCs cores and further modification of red blood cells (RBC) membranes and ferritin. Benefiting from the involvement of ferritin, the prepared AE@RBC/Fe NCs provide not only sufficient oxygen for oxygen-dependent PDT, but also Fe for iron-dependent ferroptosis in tumor cells. Furthermore, the biomimetic surface functionalization facilitated the prolonged circulation and cancer targeting of AE@RBC/Fe NCs in vivo. The in vitro and in vivo results demonstrate that AE@RBC/Fe NCs exhibit significantly enhanced therapeutic effects for the combined two antitumor mechanisms and provide a promising prospect for achieving PDT/ferroptosis synergistic therapy.
作为一种新型的非细胞凋亡性细胞死亡途径,铁死亡可以通过破坏细胞内氧化还原平衡有效增强光动力疗法(PDT)的抗肿瘤作用。然而,已报道的将 PDT 和铁死亡相结合的纳米复合材料制备繁琐,并且不利的肿瘤微环境也严重干扰了其肿瘤抑制作用。为了解决这一固有障碍,本研究试图探索能够激活铁死亡途径的光敏剂,并发现基于其对谷胱甘肽 S-转移酶 P1(GSTP1)的特定抑制活性,光敏剂大黄素(AE)可以诱导细胞铁死亡,GSTP1 是铁死亡的关键蛋白。在此,我们通过一步乳化法制备了具有协同 PDT 和铁死亡治疗效果的 AE@RBC/Fe 纳米晶体(NCs),以获得 AE NCs 核,并进一步修饰红细胞(RBC)膜和铁蛋白。得益于铁蛋白的参与,所制备的 AE@RBC/Fe NCs 不仅为依赖氧的 PDT 提供了足够的氧气,而且为肿瘤细胞中铁依赖性铁死亡提供了铁。此外,仿生表面功能化促进了 AE@RBC/Fe NCs 在体内的延长循环和癌症靶向。体外和体内结果表明,AE@RBC/Fe NCs 对联合两种抗肿瘤机制表现出显著增强的治疗效果,并为实现 PDT/铁死亡协同治疗提供了有前景的前景。
J Control Release. 2022-12
Cancers (Basel). 2023-10-19
J Control Release. 2022-10
Naunyn Schmiedebergs Arch Pharmacol. 2024-12-19
Int J Nanomedicine. 2024
Nano Lett. 2024-7-10
J Nanobiotechnology. 2024-4-1